FP 83: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3395 |
| CHEMBL ID | 3183067 |
| CHEBI ID | 31627 |
| SCHEMBL ID | 1649401 |
| MeSH ID | M0165215 |
| Synonym |
|---|
| AC-455 |
| flurbiprofen axetil |
| fp-83 |
| ropion |
| (1,1'-biphenyl)-4-acetic acid, 2-fluoro-alpha-methyl-, 1-(acetyloxy)ethyl ester |
| lipo-flurbiprofen axetil |
| lfp 83 |
| 1-acetoxyethyl 2-(2-fluoro-4-biphenylyl)propionate |
| 2-fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid 1-(acetyloxy)ethyl ester |
| 1-acetoxyethyl-2-(2-fluoro-4-biphenylyl)propionate |
| 4-biphenylacetic acid, 2-fluoro-alpha-methyl-, 1-acetoxyethyl ester |
| liposomal flurbiprofen axetil |
| lipfen |
| flurbiprofen axetil (jan) |
| 91503-79-6 |
| fp 83 |
| ropion (tn) |
| D01475 |
| 1-acetoxyethyl 2-(2-fluorobiphenyl-4-yl)propanoate |
| FT-0668761 |
| 1-acetyloxyethyl 2-(3-fluoro-4-phenylphenyl)propanoate |
| NCGC00182710-02 |
| NCGC00182710-01 |
| lfp83 |
| cas-91503-79-6 |
| tox21_113023 |
| dtxsid8048600 , |
| dtxcid1028526 |
| tox21_113023_1 |
| 1-acetoxyethyl-2-(2-fluoro-4-biphenyl)propionate |
| fp83 |
| i0ou31pui5 , |
| unii-i0ou31pui5 |
| flurbiprofen axetil [jan] |
| (1,1'-biphenyl)-4-acetic acid, 2-fluoro-.alpha.-methyl-, 1-(acetyloxy)ethyl ester |
| lfp-83 |
| flurbiprofen axetil [who-dd] |
| S6457 |
| ropiopn |
| 1-acetoxyethyl 2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanoate |
| SCHEMBL1649401 |
| AKOS024464989 |
| CHEMBL3183067 |
| J-521373 |
| CHEBI:31627 |
| F17835 |
| acetoxyethyl 2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanoate |
| DS-8257 |
| ropion; ropiopn; lipfen; lfp-83 |
| BCP21336 |
| mfcd00900049 |
| DB14938 |
| flurbiprofen axetil,(s) |
| HY-101481 |
| lfp 83;ropiopn;lfp-83;lfp83 |
| AMY18543 |
| CS-0021519 |
| Q27280207 |
| A855151 |
| F1176 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The paper is to report the establishment of a population pharmacokinetic model for flurbiprofen (FP), an active metabolite of flurbiprofen axetil (FA)." | ( [Population pharmacokinetic modeling of flurbiprofen]. Gong, SJ; Huang, PF; Lin, WW; Wang, CL, 2010) | 0.36 |
| " Therefore, it is of great significance to compare the in vivo pharmacokinetic behaviors of R-FP and S-FP." | ( Comparison of in vivo pharmacokinetic behaviors of R- and S-flurbiprofen after intravenous injection of flurbiprofen axetil. He, Y; Li, M; Qin, F; Qin, M; Tian, B; Zhi, D, 2023) | 0.91 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "To observe the effect of propofol combined with flurbiprofen axetil for abortion anesthesia." | ( [Clinical observation of propofol combined with flurbiprofen axetil for induced abortion anesthesia]. Guo, QL; Xie, YQ; Yang, HW, 2006) | 0.33 |
| "Propofol combined with flurbiprofen axetil gives more efficient anesthesia for induced abortion patients in gynecology department." | ( [Clinical observation of propofol combined with flurbiprofen axetil for induced abortion anesthesia]. Guo, QL; Xie, YQ; Yang, HW, 2006) | 0.33 |
| "a To observe the analgesic effect of fentanyl combined with flurbiprofen axetil for postoperative analgesia after gynecologic surgery." | ( [Postoperative analgesia with fentanyl combined with flurbiprofen axetil following gynecologic surgery for turnor]. Bai, XH; Cao, LH; Lin, WQ; Wen, LL; Zhong, ZJ, 2009) | 0.35 |
| "Flurbiprofen axetil combined with fentanyl for postoperative analgesia can significantly reduce fentanyl dose and the incidence of adverse effects associated with fentanyl without obviously affecting the coagulation and gastrointestinal functions." | ( [Postoperative analgesia with fentanyl combined with flurbiprofen axetil following gynecologic surgery for turnor]. Bai, XH; Cao, LH; Lin, WQ; Wen, LL; Zhong, ZJ, 2009) | 0.35 |
| "EA intervention combined with anesthetics is effective in reducing the dosage of the supplemented Sauteralgyl and the degree of postoperative nausea, and in improving postoperative gastrointestinal functional recovery in patients undergoing pneumectomy." | ( [Electroacupuncture Intervention Combined with Anesthetics for Analgesia and Post-surgical Gastrointestinal Recovery in Pneumectomy Patients]. Chen, TY; Ma, W; Wang, K; Wu, YY; Xu, JJ; Zhou, J, 2015) | 0.42 |
| " We hypothesize that different doses of oxycodone hydrochloride combined with flurbiprofen axetil would generate great results on postoperative intravenous analgesia in lower abdominal patients." | ( Effect of oxycodone hydrochloride combined with flurbiprofen axetil for intravenous patient-controlled analgesia in lower abdominal patients: A randomized trial. Fang, J; Lian, Y; Wu, Y; Xiang, X; Yuan, X, 2018) | 0.48 |
| "75 mg/kg oxycodone hydrochloride combined with flurbiprofen axetil can provide safe and effective postoperative analgesia for lower abdominal patients, with fewer adverse reactions." | ( Effect of oxycodone hydrochloride combined with flurbiprofen axetil for intravenous patient-controlled analgesia in lower abdominal patients: A randomized trial. Fang, J; Lian, Y; Wu, Y; Xiang, X; Yuan, X, 2018) | 0.48 |
| " Nonetheless, only few studies have evaluated the clinical therapeutic effects of lidocaine combination with flurbiprofen axetil to prevent pain on injection of propofol." | ( Clinical therapeutic effects of lidocaine combination with flurbiprofen axetil for reducing propofol-induced pain in adults: A protocol for systematic review and meta-analysis. Fu, J; Lu, G; Sun, W; Ye, X; Yu, J, 2020) | 0.56 |
| "This study will provide high-quality evidence for the clinical therapeutic effects of lidocaine combination with flurbiprofen axetil for reducing pain on injection of propofol in adult patients." | ( Clinical therapeutic effects of lidocaine combination with flurbiprofen axetil for reducing propofol-induced pain in adults: A protocol for systematic review and meta-analysis. Fu, J; Lu, G; Sun, W; Ye, X; Yu, J, 2020) | 0.56 |
| "To evaluate the safety and efficacy of sedation and analgesia using dexmedetomidine combined with flurbiprofen axetil in multiple complex teeth extraction under local anesthesia." | ( [Evaluation of the application of dexmedetomidine combined with flurbiprofen axetil in extraction of multiple complex teeth under local anesthesia]. He, H; Liu, H; Qi, M; Shao, Y; Sheng, L, 2021) | 0.62 |
| "According to the inclusion and exclusion criteria of the study, 40 patients scheduled for multiple complex teeth (4-6) extraction were randomly divided into 2 groups: experimental group (sedation and analgesia using dexmedetomidine combined with flurbiprofen axetil in addition to local anesthesia, n=20) and control group (local anesthesia, n=20)." | ( [Evaluation of the application of dexmedetomidine combined with flurbiprofen axetil in extraction of multiple complex teeth under local anesthesia]. He, H; Liu, H; Qi, M; Shao, Y; Sheng, L, 2021) | 0.62 |
| "Sedation and analgesia using dexmedetomidine combined with flurbiprofen axetil in addition to local anesthesia is a safe and effective approach in multiple complex teeth extraction." | ( [Evaluation of the application of dexmedetomidine combined with flurbiprofen axetil in extraction of multiple complex teeth under local anesthesia]. He, H; Liu, H; Qi, M; Shao, Y; Sheng, L, 2021) | 0.62 |
| "To explore the effect of dexmedetomidine combined with flurbiprofen axetil on postoperative analgesia and immune function in patients with lung cancer after radical operation." | ( Application effect of dexmedetomidine combined with flurbiprofen axetil and flurbiprofen axetil monotherapy in radical operation of lung cancer and evaluation of the immune function. Chen, Y; Du, J; Tao, H; Zong, S, ) | 0.13 |
| "60 lung cancer patients undergoing open chest radical surgery were selected and randomly divided into D & F Group (dexmedetomidine combined with flurbiprofen axetil) and F Group (flurbiprofen axetil), with 30 cases in each group." | ( Application effect of dexmedetomidine combined with flurbiprofen axetil and flurbiprofen axetil monotherapy in radical operation of lung cancer and evaluation of the immune function. Chen, Y; Du, J; Tao, H; Zong, S, ) | 0.13 |
| "Flurbiprofen axetil can improve postoperative pain, but combined with dexmedetomidine better effect, postoperative comfort and immune function of patients were significantly improved." | ( Application effect of dexmedetomidine combined with flurbiprofen axetil and flurbiprofen axetil monotherapy in radical operation of lung cancer and evaluation of the immune function. Chen, Y; Du, J; Tao, H; Zong, S, ) | 0.13 |
| "To investigated the effects of sufentanil in combination with flurbiprofen axetil and dexmedetomidine for patient-controlled intravenous analgesia (PCIA) on patients after open gastrointestinal tumor surgery, and compared this combination with traditional PCIA with pure opioids or epidural analgesia (PCEA)." | ( Analgesic effects of sufentanil in combination with flurbiprofen axetil and dexmedetomidine after open gastrointestinal tumor surgery: a retrospective study. Chen, YJ; Huang, J; Li, TT; Liu, F; Wang, TH; Xiong, LL; Yin, L, 2022) | 0.72 |
| "The analgesic effects of PCIA with sufentanil in combination with flurbiprofen axetil and dexmedetomidine on postoperative analgesia was better than that of traditional pure opioids PCIA, and similar with that of PCEA." | ( Analgesic effects of sufentanil in combination with flurbiprofen axetil and dexmedetomidine after open gastrointestinal tumor surgery: a retrospective study. Chen, YJ; Huang, J; Li, TT; Liu, F; Wang, TH; Xiong, LL; Yin, L, 2022) | 0.72 |
| " This study aimed to compare the analgesic effects of tramadol alone and combined with butorphanol or flurbiprofen axetil after a cesarean section." | ( Analgesic outcomes of tramadol alone and in combination with Butorphanol or Flurbiprofen Axetil after cesarean section: a retrospective study with propensity score matching analysis. Bao, X; Deng, Q; Li, H; Liang, Y; Liu, W; Peng, J; Tan, D; Wu, Z; Yan, G; Yang, G, 2022) | 0.72 |
| "To determine the analgesic effect of flurbiprofen axetil (FBA) combined with half standard-dose opioids in patients undergoing primary unilateral total knee arthroplasty (TKA)." | ( Analgesia with reduced incidence of adverse reactions using flurbiprofen axetil in combination with half standard-dose opioids in primary total knee arthroplasty. Cai, H; Lin, Q; Liu, J; Shen, J; Wu, X; Xiao, J; Zhao, C; Zhu, J, 2023) | 0.91 |
| " All patients received the same dose of FBA in the form of a patient-controlled intravenous analgesia but in the control group this was combined with a standard-dose of opioids and in the experimental group with a half standard-dose of opioids." | ( Analgesia with reduced incidence of adverse reactions using flurbiprofen axetil in combination with half standard-dose opioids in primary total knee arthroplasty. Cai, H; Lin, Q; Liu, J; Shen, J; Wu, X; Xiao, J; Zhao, C; Zhu, J, 2023) | 0.91 |
| "The analgesic effect of FBA in combination with half standard-dose opioids was similar to that of FBA in combination with conventional standard-dose opioids, but the incidence of adverse effects involving nausea/vomiting in the experimental group were significantly reduced." | ( Analgesia with reduced incidence of adverse reactions using flurbiprofen axetil in combination with half standard-dose opioids in primary total knee arthroplasty. Cai, H; Lin, Q; Liu, J; Shen, J; Wu, X; Xiao, J; Zhao, C; Zhu, J, 2023) | 0.91 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "9 times higher than that of the flurbiprofen sodium eye drops respectively, which meant that the ocular bioavailability was improved greatly by the novel preparation." | ( [Ion-sensitive nanoemulsion-in situ gel system for ophthalmic delivery of flurbiprofen axetil]. Gan, L; Gan, Y; Shen, JQ; Zhu, CL; Zhu, JB, 2010) | 0.36 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have examined the inhibitory effect of free fatty acid (FFA), a binding inhibitor for site II of HSA, on the binding of flurbiprofen in-vitro and in-vivo by ultrafiltration, to establish an effective dosage of FP-ax." | ( Dosage plan of a flurbiprofen injection product using inhibition of protein binding by lipid emulsion in rats. Arimori, K; Higuchi, S; Kawai, K; Ogata, K; Takamura, N; Tokunaga, J, 2008) | 0.35 |
| " In three other groups (n = 8 in each group), the selected dosage of 10 mg/kg was administrated intravenously at 6, 12 and 24 hours after I/R." | ( Therapeutic time window of flurbiprofen axetil's neuroprotective effect in a rat model of transient focal cerebral ischemia. Dong, HL; Liu, JL; Lu, Y; Sang, HF; Wang, C; Xiong, LZ, 2008) | 0.35 |
| " A novel population pharmacokinetic model is developed to estimate the individual pharmacokinetic parameter for patients intravenous injecting FA in terms of patients' characteristics and dosing history, and to design a prior dosage regimen." | ( [Population pharmacokinetic modeling of flurbiprofen]. Gong, SJ; Huang, PF; Lin, WW; Wang, CL, 2010) | 0.36 |
| "Compared with the control group, the VAS score at 48 h after surgery, and the dosage of the supplemented Sauteralgyl were evidently lower, and the time of both exhaust and defecation after surgery was significantly earlier, and the degree of nausea after surgery was obviously milder in patients of the EA group (P<0." | ( [Electroacupuncture Intervention Combined with Anesthetics for Analgesia and Post-surgical Gastrointestinal Recovery in Pneumectomy Patients]. Chen, TY; Ma, W; Wang, K; Wu, YY; Xu, JJ; Zhou, J, 2015) | 0.42 |
| "EA intervention combined with anesthetics is effective in reducing the dosage of the supplemented Sauteralgyl and the degree of postoperative nausea, and in improving postoperative gastrointestinal functional recovery in patients undergoing pneumectomy." | ( [Electroacupuncture Intervention Combined with Anesthetics for Analgesia and Post-surgical Gastrointestinal Recovery in Pneumectomy Patients]. Chen, TY; Ma, W; Wang, K; Wu, YY; Xu, JJ; Zhou, J, 2015) | 0.42 |
| " The pain intensity, consumed sufentanil dosage of the PCA, and the side effects was not different between groups." | ( Effect of flurbiprofen axetil on postoperative delirium for elderly patients. Chen, H; Han, F; Hu, Y; Wang, L; Wang, X; Wang, Y; Wei, L; Zhao, W, 2019) | 0.51 |
| " The present study tested the hypothesis that multimodal analgesia with combined ropivacaine wound infiltration and intravenous flurbiprofen axetil after radical thyroidectomy provided better analgesia than a single dosage of tramadol." | ( Multimodal analgesia with ropivacaine wound infiltration and intravenous flurbiprofen axetil provides enhanced analgesic effects after radical thyroidectomy: a randomized controlled trial. Li, X; Tan, H; Yang, J; Yu, L, 2019) | 0.51 |
| " The dosage of sufentanil and the times of pressing analgesia pump in group D & F were significantly less than those in group F (p<0." | ( Application effect of dexmedetomidine combined with flurbiprofen axetil and flurbiprofen axetil monotherapy in radical operation of lung cancer and evaluation of the immune function. Chen, Y; Du, J; Tao, H; Zong, S, ) | 0.13 |
| Class | Description |
|---|---|
| organic molecular entity | Any molecular entity that contains carbon. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 38.9018 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 0.9439 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 26.6032 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 2.9849 | 0.0010 | 22.6508 | 76.6163 | AID1224838 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 15.4907 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075 |
| G | Vesicular stomatitis virus | Potency | 9.7717 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 13.8029 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| caspase-3 | Homo sapiens (human) | Potency | 26.6032 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| Interferon beta | Homo sapiens (human) | Potency | 9.7717 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 9.7717 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 29.8493 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 5.6234 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 9.7717 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 9.7717 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (2.04) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (15.31) | 29.6817 |
| 2010's | 56 (57.14) | 24.3611 |
| 2020's | 25 (25.51) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (9.82) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 58 (56.86%) | 5.53% |
| Reviews | 2 (1.96%) | 6.00% |
| Case Studies | 2 (1.96%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 40 (39.22%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||